证券代码：301293 证券简称：三博脑科 公告编号：2026-005 三博脑科医院管理集团股份有限公司 关于办公地址变更的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 因经营发展需要，三博脑科医院管理集团股份有限公司（以下简称"公司"） 于近日搬迁至新办公地址。为便于投资者与公司沟通交流，现将公司办公地址变 更的情况公告如下： | 变更事项 | 变更前 | | 变更后 | | | | --- | --- | --- | --- | --- | --- | | 办公地址 | 北京市海淀区香山一棵松 | 50 | 北京市海淀区板井路 | 69 | 号世纪 | | | 号 23 号楼 | | 金源商务中心写字楼 | 3 | 层 A | | 邮政编码 | 100093 | | 100097 | | | 公司对外披露的办公地址、董事会秘书和证券事务代表联系地址、公司年度 报告备置地点同步变更。公司注册地址、网址、联系电话、传真、电子邮箱等其 他信息均保持不变。 以上办公地址自公告之日起正式启用，公司后续将及时办理注册地址变更及 ...

Group 1 - The core viewpoint of the news is the performance and financial details of Sanbo Brain Science Hospital Management Group Co., Ltd, which saw a stock price increase of 5.12% to 80.28 CNY per share, with a trading volume of 601 million CNY and a market capitalization of 16.537 billion CNY [1] - The company, established on November 25, 2003, and listed on May 5, 2023, primarily provides medical services, with revenue composition as follows: 74.35% from medical services, 25.02% from pharmaceuticals, 0.39% from other sources, and 0.24% from supply chain [1] Group 2 - From the perspective of the top ten circulating shareholders, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 749,300 shares in the third quarter, now holding 4.0556 million shares, which accounts for 2.52% of the circulating shares [2] - The estimated floating profit from this reduction is approximately 15.8575 million CNY [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 25.263 billion CNY, yielding 4.83% this year, ranking 3398 out of 5551 in its category, and 14.55% over the past year, ranking 3650 out of 4285 [2] Group 3 - The fund manager of Huabao CSI Medical ETF is Hu Jie, who has a cumulative tenure of 13 years and 109 days, managing total assets of 101.358 billion CNY [3] - During Hu Jie's tenure, the best fund return was 161.34%, while the worst was -98.01% [3]

Group 1 - Tianqi Co., Ltd. has entered the brain-computer interface (BCI) sector by investing in Suzhou Huahui Chip, focusing on high-density flexible neural electrode technology, achieving animal testing stages, and becoming a key player in domestic BCI hardware localization. The developed flexible neural electrode has 1024 channels, with signal acquisition precision and anti-interference capabilities at an internationally advanced level. The company has also completed biocompatibility surface modification technology to reduce inflammation after electrode implantation, with core patents authorized by the National Intellectual Property Administration [1][2][3] - Innovation Medical, through its subsidiary Boling Brain Machine, is one of the first companies in China to commercialize BCI rehabilitation products. The core product, Cyberlink AC5, was officially launched in October 2025, generating sales revenue of 114,000 yuan in 2025. Another product, Cyberlink AM5, has completed multi-center clinical trials and is progressing through the approval process. The company plans to establish five additional clinical cooperation centers to accelerate the application of BCI technology in treating neurological diseases [4][5][6] - iFlytek is a leading company in the non-invasive BCI field, leveraging its artificial intelligence technology to develop BCI collaborative technology. The company has established long-term partnerships with universities for research and development. Its non-invasive BCI system has been piloted in 120 schools nationwide, improving student attention by 30%. In the medical field, a collaboration with Beijing Tiantan Hospital has achieved a 92% accuracy rate in identifying abnormal brain signals for epilepsy [7][8][9] Group 2 - Jiahe Intelligent focuses on the research and mass production of BCI hardware, particularly EEG acquisition devices and core components, serving both consumer and medical-grade markets. The company has achieved large-scale production of EEG acquisition headphones with a signal recognition accuracy of 92%, primarily used in sleep monitoring and attention training. It plans to expand into overseas BCI hardware markets by 2026 [10][11][12] - Tom Cat is the first company in China to apply BCI technology in consumer scenarios, focusing on interactive games and rehabilitation training products. The company launched a mind-controlled game product in 2025, which quickly gained over 500,000 users. It also collaborates with rehabilitation institutions to develop BCI rehabilitation training systems, showing a 35% average improvement in patient motor function scores [13][14][15] - Hanwei Technology, through its subsidiary Weisheng Technology, is a leading company in the EEG sensor field, with an annual shipment of over 2 million units. The company has developed an epilepsy early warning system with an 88% accuracy rate in clinical tests. It also focuses on flexible pressure sensors for invasive BCI electrodes, addressing industry pain points [16][17][18] Group 3 - StarNet Ruijie leverages its network communication technology to develop low-power, high-stability EEG signal transmission systems and data encryption modules, becoming a core supplier for BCI data links. The developed transmission system supports real-time transmission of 1024-channel EEG signals with a latency of less than 10ms and a stability of 99.9% [19][20][21] - Yijiahe focuses on the integration of BCI and embodied intelligent robots, exploring applications in smart healthcare. The company has signed a strategic cooperation agreement to develop real-time emotional companionship and brain-controlled robots, enhancing the emotional care capabilities of robots [22][23][24] - Lihua Technology is focused on incubating and investing in the BCI sector, successfully incubating three high-tech companies in the field. The company collaborates with the Shenzhen Institute of Advanced Technology to provide comprehensive services for incubated companies, addressing development pain points [25][26][27] Group 4 - Sanbo Neurosurgery is a leading private hospital in the neurosurgery field, focusing on the clinical application and research of BCI. The company has successfully conducted an interventional BCI surgery, accumulating valuable experience for clinical applications. It is also recruiting participants for ongoing clinical trials [28][29][30] - Shiyun Circuit is a core enterprise in the PCB field, providing customized PCB products for BCI devices. The company focuses on high-density, flexible PCB designs, achieving low signal loss rates below 2% [31][32][33] - Meihua Medical is a leading supplier of core components for BCI, having entered the core supply chain for invasive BCI products. The company has developed components that have passed biocompatibility tests, ensuring long-term stability and safety for implanted devices [34][35][36]

Market Overview - The medical services sector experienced a decline of 1.41% on January 26, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable gainers in the medical services sector included: - Guangzheng Eye Hospital (002524) with a closing price of 5.05, up 10.02% on a trading volume of 266,400 shares and a transaction value of 132 million [1] - Lanwei Medical (301060) closed at 12.28, up 3.98% with a trading volume of 325,000 shares and a transaction value of 392 million [1] - Major decliners included: - Meidisi (688202) closed at 60.88, down 7.28% with a trading volume of 71,600 shares and a transaction value of 444 million [2] - Meinian Health (002044) closed at 7.26, down 6.08% with a trading volume of 3.7675 million shares and a transaction value of 2.776 billion [2] Capital Flow - The medical services sector saw a net outflow of 1.318 billion from institutional investors, while retail investors had a net inflow of 1.011 billion [2] - The capital flow for specific stocks showed: - Boteng Co. (300363) had a net outflow of 39.83 million from institutional investors [3] - Guangzheng Eye Hospital (002524) had a net inflow of 39.29 million from institutional investors [3] - Lanwei Medical (301060) had a net inflow of 24.71 million from institutional investors [3]

本报讯（记者孙杰）今天，首都医科大学三博脑科东坝新院区正式开诊。 三博脑科医院于2004年由一批神经外科专家参与创建而成，是一家集医疗、教学、科研为一体的学院型 医院。东坝新院区位于朝阳区东坝中路36号1号楼，地铁3号线东坝南站出站即到。医院总建筑面积6.3 万平方米，共设置480张床位，13间手术间，并配备复合手术室及术中核磁共振等大型设备。 记者在新院区看到，新院区整洁明亮，各项医疗服务功能完善。以中间的门诊大厅为界，院区分为南北 两楼，北楼主要是神经肿瘤、特需病房和研究型病房；南楼主要是功能神经外科、脑血管病、小儿神经 外科、脊柱脊髓外科及骨科等。 新院区预计年门诊量将超10万人次，此次新引进多台大型设备，并采用智能化技术提升医疗服务体验。 比如，门诊药房采用智能机器人分拣药品，并通过传送带送至药房窗口。每个处方的药品从分拣到窗 口，大约仅需15秒钟就可完成。 ...

Core Viewpoint - The company Sanbo Brain Science (301293.SZ) is relocating its hospital to a new site, with operations commencing on January 26 at 8:00 AM [1] Company Overview - Sanbo Brain Science was founded by experts in neurology and medical management, including renowned figures such as Luan Guoming, Yu Chunjiang, Shi Xiangen, and Zhang Yang [1] - The company has developed into a specialized chain group focusing on neurological diseases over more than 20 years, establishing itself as a leader in the neurology specialty field in China [1]

Core Viewpoint - The new East Ba District branch of Capital Medical University Sanbo Brain Hospital is set to officially open on January 26, enhancing regional medical resources and services [1][8]. Group 1: Hospital Overview - The new hospital is located at No. 36 East Ba Middle Road, Chaoyang District, with a total construction area of 63,000 square meters, featuring 480 beds and 13 operating rooms, including advanced surgical facilities [5][12]. - The hospital aims to serve over 100,000 outpatient visits annually, utilizing smart technology to improve patient experience, such as a robotic pharmacy that can sort and deliver medications in approximately 15 seconds [12][14]. Group 2: Services and Specializations - The hospital is designed as a "large specialty, small comprehensive" facility, focusing on neurology while also developing emergency, pediatric neurology, critical care, pain management, rehabilitation, and traditional Chinese medicine departments [16][19]. - The hospital will establish five centers: International Neurological Consultation Center, Brain Health Management Center, Difficult Critical Illness Diagnosis Center, High-end Talent Training Center, and Medical Achievement Transformation Center [19]. Group 3: Community Impact - The East Ba District has a dense population, and the new hospital is expected to meet the local demand for accessible healthcare services, with residents expressing anticipation for its opening [16][19]. - The hospital's strategic location and expanded services aim to address the diverse medical needs of the surrounding community [16][19].

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% over the next 6 months [14]. Core Insights - A breakthrough in Alzheimer's treatment was observed when a focused ultrasound surgery unexpectedly improved the cognitive function of a patient, challenging the traditional belief that Alzheimer's is irreversible. This condition affects nearly 17 million patients in China, leading to significant caregiving burdens [4][5]. - The research team led by Professor Sun Bomin is exploring a new approach using high-energy ultrasound to directly stimulate brain neural circuits, with initial clinical trials showing an average improvement rate of about 50% among seven moderate to severe patients [5]. - The global brain-computer interface (BCI) market is projected to grow rapidly, with an estimated size of approximately $2.62 billion in 2024, reaching $2.94 billion in 2025, and potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate of 17.35% over the next decade [6]. Summary by Sections Industry Overview - The report highlights the significant unmet medical need in Alzheimer's treatment and the potential for innovative therapies to emerge from recent clinical findings [4][5]. Market Potential - The brain-computer interface market is expected to see substantial growth, with specific projections for both global and Chinese markets, indicating a strategic focus on high-tech industries as outlined in national economic plans [6]. Investment Recommendations - The report suggests monitoring companies such as Yanshan Technology, Hanwei Technology, Sanbo Brain Science, and others, which are positioned to benefit from advancements in the BCI and related technologies [6].

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the 28 sectors in the Shenwan classification experiencing gains, led by the construction materials and defense industries, which increased by 4.09% and 3.23% respectively [1] - The beauty and banking sectors saw the largest declines, with decreases of 0.76% and 0.43% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 21.612 billion yuan, with 12 sectors experiencing net inflows [1] - The telecommunications sector had the highest net inflow, amounting to 8.019 billion yuan, and it rose by 2.83% [1] - The defense industry also saw significant inflow, with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - The electronics sector faced the largest net outflow, totaling 13.206 billion yuan, followed by the power equipment sector with an outflow of 7.206 billion yuan [1] Pharmaceutical and Biological Industry Performance - The pharmaceutical and biological sector declined by 0.42%, with a net capital outflow of 3.027 billion yuan [2] - Out of 478 stocks in this sector, 253 rose while 204 fell, with 2 stocks hitting the daily limit up [2] - The top three stocks with the highest net inflow were Sanbo Brain Science (1.42 billion yuan), Yunnan Baiyao (667.561 million yuan), and Innovation Medical (637.008 million yuan) [2] - The sector's outflow was led by Hengrui Medicine, which saw a net outflow of 372.7538 million yuan, followed by Xingqi Eye Medicine and Aidi Pharmaceutical with outflows of 208.3529 million yuan and 121.6946 million yuan respectively [3]